Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle
Objective: The objective of this study was to evaluate the safety of using tegafur–uracil (UFT) in colorectal cancer patients with partial dihydropyrimidine dehydrogenase (DPD) deficiency. Patients and Methods: The study included five colorectal cancer patients who presented with acute toxicity (gra...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2012-07-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/1758834012441049 |
| _version_ | 1819093657003753472 |
|---|---|
| author | Daniel I.G. Cubero Felipe Melo Cruz Patrícia Santi Ismael Dale C.G. Silva Auro del Giglio |
| author_facet | Daniel I.G. Cubero Felipe Melo Cruz Patrícia Santi Ismael Dale C.G. Silva Auro del Giglio |
| author_sort | Daniel I.G. Cubero |
| collection | DOAJ |
| description | Objective: The objective of this study was to evaluate the safety of using tegafur–uracil (UFT) in colorectal cancer patients with partial dihydropyrimidine dehydrogenase (DPD) deficiency. Patients and Methods: The study included five colorectal cancer patients who presented with acute toxicity (grades 3 and 4) after being given the first cycle of chemotherapy using 5-fluorouracil. The DPD deficiency was confirmed by gene sequencing. After a full recovery from all side effects, we changed the regimen to UFT (300 mg/m 2 /day) associated with leucovorin (90 mg/day) for 21 days, with an empirical dose reduction of at least 10% in the first cycle. Results: We prospectively analysed 22 UFT cycles in 5 patients. We did not observe any episodes of grade 3 or 4 toxicity. The predominant toxicities were of grades 1 and 2 (nausea, vomiting and diarrhoea). Conclusion: Here, we demonstrate a complete absence of severe toxicity in all patients and cycles analysed. We believe that UFT is a safe alternative for the treatment of patients with partial DPD deficiency. |
| first_indexed | 2024-12-21T23:14:59Z |
| format | Article |
| id | doaj.art-2b144bac3fad407f9bfd8f9abfaf8c00 |
| institution | Directory Open Access Journal |
| issn | 1758-8340 1758-8359 |
| language | English |
| last_indexed | 2024-12-21T23:14:59Z |
| publishDate | 2012-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-2b144bac3fad407f9bfd8f9abfaf8c002022-12-21T18:46:56ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83401758-83592012-07-01410.1177/1758834012441049Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principleDaniel I.G. CuberoFelipe Melo CruzPatrícia SantiIsmael Dale C.G. SilvaAuro del GiglioObjective: The objective of this study was to evaluate the safety of using tegafur–uracil (UFT) in colorectal cancer patients with partial dihydropyrimidine dehydrogenase (DPD) deficiency. Patients and Methods: The study included five colorectal cancer patients who presented with acute toxicity (grades 3 and 4) after being given the first cycle of chemotherapy using 5-fluorouracil. The DPD deficiency was confirmed by gene sequencing. After a full recovery from all side effects, we changed the regimen to UFT (300 mg/m 2 /day) associated with leucovorin (90 mg/day) for 21 days, with an empirical dose reduction of at least 10% in the first cycle. Results: We prospectively analysed 22 UFT cycles in 5 patients. We did not observe any episodes of grade 3 or 4 toxicity. The predominant toxicities were of grades 1 and 2 (nausea, vomiting and diarrhoea). Conclusion: Here, we demonstrate a complete absence of severe toxicity in all patients and cycles analysed. We believe that UFT is a safe alternative for the treatment of patients with partial DPD deficiency.https://doi.org/10.1177/1758834012441049 |
| spellingShingle | Daniel I.G. Cubero Felipe Melo Cruz Patrícia Santi Ismael Dale C.G. Silva Auro del Giglio Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle Therapeutic Advances in Medical Oncology |
| title | Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle |
| title_full | Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle |
| title_fullStr | Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle |
| title_full_unstemmed | Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle |
| title_short | Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle |
| title_sort | tegafur uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency a proof of principle |
| url | https://doi.org/10.1177/1758834012441049 |
| work_keys_str_mv | AT danieligcubero tegafururacilisasafealternativeforthetreatmentofcolorectalcancerinpatientswithpartialdihydropyrimidinedehydrogenasedeficiencyaproofofprinciple AT felipemelocruz tegafururacilisasafealternativeforthetreatmentofcolorectalcancerinpatientswithpartialdihydropyrimidinedehydrogenasedeficiencyaproofofprinciple AT patriciasanti tegafururacilisasafealternativeforthetreatmentofcolorectalcancerinpatientswithpartialdihydropyrimidinedehydrogenasedeficiencyaproofofprinciple AT ismaeldalecgsilva tegafururacilisasafealternativeforthetreatmentofcolorectalcancerinpatientswithpartialdihydropyrimidinedehydrogenasedeficiencyaproofofprinciple AT aurodelgiglio tegafururacilisasafealternativeforthetreatmentofcolorectalcancerinpatientswithpartialdihydropyrimidinedehydrogenasedeficiencyaproofofprinciple |